Abstract: To investigate the cost-effectiveness of different screening intervals for diabetic retinopathy (DR) in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM).

Chinese healthcare system.

A cost-effectiveness model was developed to simulate the disease course of Chinese population with newly diagnosed with diabetes. Different DR screening programs were modeled to project economic outcomes. To develop the economic model, we calibrated the progression rates of DR that fit Chinese epidemiologic data derived from the published literature. Costs were estimated from the perspective of the Chinese healthcare system, and the analysis was run over a lifetime horizon. One-way and probabilistic sensitivity analyses were performed. Total costs, vision outcomes, costs per quality-adjusted life year (QALY), the incremental cost-effectiveness ratio (ICER) of screening strategies compared to no screening.

DR screening is effective in Chinese patients with newly diagnosed T2DM, and screening strategies with ≥4-year intervals were cost-effective (ICER <$7485 per QALY) compared to no screening. Screening every 4 years produced the greatest increase in QALYs (11.066) among the cost-effective strategies. The screening intervals could be varied dramatically by age at T2DM diagnosis. Probabilistic sensitivity analyses demonstrated the consistency and robustness of the cost-effectiveness of the 4-year interval screening strategy.

The findings suggest that a 4-year interval screening strategy is likely to be more cost-effective than screening every 1 to 3 years in comparison with no screening in the Chinese setting. The screening intervals might be tailored according to the age at T2DM diagnosis.

(Medicine 94(45):c1989)

Abbreviations: DES = discrete event simulation, DME = diabetic macular edema, DR = diabetic retinopathy, ICER = incremental cost-effectiveness ratio, LYS = life years, ME = macular edema.
A simulation (DES) policy model was developed to measure the economic and health outcomes of DR screening. The main reason that a DES was selected is that this model can closely replicate the disease course with the more powerful flexibility in handling perspectives and structural variations with few restrictions in comparison with the decision trees and Markov models. When the model begins to simulate, we created hypothetical patients with specific characteristics, which was then duplicated to generate several identical cohorts for assessing the different strategies. All of the potential risks and events would be incurred by patients during the course of disease simulation. The event with the shortest time of arrival would be chosen as the occurred event. The time of arrival for each type of event was randomly sampled based on the statistical distribution of happening time. Once the event arrived, the attributes of patients would then be renewed instantaneously for recalculating the risks and event times.

The patients who were included in the model at baseline reflected the characteristics of Chinese patients with type 2 diabetes, including the age, sex, and disease status of DR at the diagnosis time point. A hypothetical patient population with newly diagnosed type 2 diabetes was created for this simulation. Each simulated patient in the cohort was assigned specific characteristics and then cloned to receive one of the following screening strategies: no DR screening or screening on 1-, 2-, 3-, 4-, 5-year interval basis. The screening strategies were chosen based on the previous studies, which showed the screening interval varied from 1 to 5 years. We assumed that patients with diagnosed NPDR, PDR, or ME were subsequently referred for annual examination. Patients with confirmed PDR or ME were treated with laser photocoagulation treatment. Risks for disease progression related to treatment were then assigned to each patient. Each patient could be subjected to the following health events as shown in Figure 1: no DR, NPDR, PDR, ME, and blind from DR (bilateral best-corrected VA < 6/60).

The primary model outputs would capture life years (LYs), quality-adjusted life years (QALYs), and the direct medical consumption, and a cost-utility analysis was performed, where incremental cost-effectiveness ratios (ICERs) were calculated by the difference in costs between strategies divided difference in their effect. The model outcomes were measured based on 100 iterations comprising a cohort of 100,000 patients until their death or 100 years old (lifetime), which was used as the time horizon of the model because diabetes and DR were lifetime diseases. Future costs and QALY outcomes were annually discounted at a rate of 3% according to the health economic evaluation guideline in China. This economic study was based on a literature review and model techniques, and did not require approval by the institutional Research Ethics Board.

**Clinical Data**

Due to the absence of relevant epidemiological studies, we cannot directly estimate the risks of NPDR, PDR, and ME in Chinese patients with type 2 diabetes. We used the calibration approach, which is a process of producing model output parameters that best predict observed data, to identify a series of good fitting parameter sets by the genetic algorithm that

![FIGURE 1. General simulation process of DR in patients with type 2 diabetes. Patients' health state could change if an event (eg, NPDR) occurred. The risks depended on the underlying disease and the treatment strategy received. DR = diabetic retinopathy; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; ME = macular edema.](image-url)
provided model predictions that were consistent with the observed Chinese prevalence of NPDR, PDR, and ME. Additional details regarding the methods used for model calibration and validation are explained in the Appendix, http://links.lww.com/MD/A519. Calibration targets were derived by conducting a literature review in PubMed, EMBASE, and the China National Knowledge Infrastructure database. The prevalences of NPDR, PDR, and ME were collected and are presented in Appendix, http://links.lww.com/MD/A519.

Mortality
Natural mortality could occur at any point during the disease course. The model used a normal life table from the life tables for the World Health Organization’s (WHO) member states (2011) to adjust the mortality multiplier for patients with diabetes and DR (Table 1).

Cost and Utility Data
Costs were estimated from the perspective of the Chinese healthcare system in the general clinical setting and are reported in 2014 US dollar equivalents (US $1 = CNY 6.2). The following direct medical cost components were considered: the costs of DR screening, drugs, regular clinic fees, laser photocoagulation (focal and scatter), and fluorescein angiogram. All unit costs of the health resources were estimated using data from the local health system or the National Development and Reform Commission (NDRC) of China.

The utility scores related to DR, including no DR, NPDR, PDR, ME, and blindness, were derived from relevant published studies. A total of 406 eligible T2DM patients with DR in Chinese Taiwan were recruited for measuring utility values by using time trade-off method.

Sensitivity Analysis
To test the robustness of the model, 1- and 2-way sensitivity analyses of the parameters were conducted in the decision model over the estimate ranges presented in Table 1. We performed probability sensitivity analyses (PSAs) in which uncertainties across all of the variables were varied simultaneously for 1000 iterations across 95% confidence intervals. In cases in which these confidence intervals were not available, we used plausible (eg, ±25%) values. Triangular distributions

### TABLE 1. Parameter Values for the Model

| Parameter | Base Case Value | Range | Source |
|-----------|----------------|-------|--------|
| Annual disease progression rates | | | |
| No DR to NPDR | 0.068 | 0.059–0.076 | Calibrated |
| NPDR to PDR | 0.026 | 0.017–0.036 | Calibrated |
| NPDR to ME | 0.080 | 0.054–0.108 | Calibrated |
| PDR to blindness with photocoagulation | 0.02 | 0.002–0.03 | 19–21 |
| PDR to blindness without photocoagulation | 0.09 | 0.05–0.11 | 19–21 |
| ME to blindness with photocoagulation | 0.03 | 0.01–0.05 | 19–21 |
| ME to blindness without photocoagulation | 0.05 | 0.03–0.07 | 19–21 |
| Mortality multipliers | | | |
| Diabetes | 1.8 | 1.6–2 | 20,22 |
| NPDR | 1.36 | 1.09–1.61 | 21–23 |
| PDR | 1.76 | 1.64–1.88 | 22 |
| ME | 1.76 | 1.64–1.88 | 22 |
| Blindness | 2.34 | 2.22–2.46 | 22 |
| Characteristics of the screening tests | | | |
| No DR called NPDR | 0.05 | 0.04–0.06 | 24–26 |
| No DR called PDR | 0.003 | 0–0.006 | 24–26 |
| NPDR called no DR | 0.22 | 0.21–0.23 | 24–26 |
| NPDR called PDR | 0.02 | 0.01–0.03 | 20,27,28 |
| PDR called no DR | 0.02 | 0.01–0.03 | 20,27,28 |
| PDR called NPDR | 0.03 | 0.02–0.04 | 20,27,28 |
| Sensitivity for ME | 0.82 | 0.7–0.94 | 20,27,28 |
| Specificity for ME | 0.79 | 0.67–0.91 | 20,27,28 |
| Cost (US $) | | | |
| Visit for dilated eye examination | 32.26 | 24.19–48.39 | Local charge |
| Scatter photocoagulation | 322.58 | 241.94–403.23 | Local charge |
| Focal photocoagulation | 322.58 | 241.94–403.23 | Local charge |
| Fluorescein angiogram | 64.52 | 48.39–145.16 | Local charge |
| Utility scores | | | |
| No DR | 0.94 | 0.93–0.95 | 29,30 |
| NPDR | 0.87 | 0.84–0.9 | 29,30 |
| PDR | 0.83 | 0.78–0.88 | 29,30 |
| Blindness | 0.81 | 0.76–0.86 | 29,30 |
| ME | 0.83 | 0.78–0.88 | 29,30 |

DR = diabetic retinopathy, ME = macular edema, NPDR = nonproliferative diabetic retinopathy, PDR = proliferative diabetic retinopathy.
Cost-effectiveness acceptability curves were constructed to summarize the uncertainty of the cost-effectiveness estimates in the context of a broader range for willingness-to-pay per QALY. In accordance with the WHO recommendation, the per capita GDP value of China in 2014 ($7485) was used as the cost-effectiveness threshold.

**RESULTS**

**Cost-Effectiveness Analysis**

Our model estimated the costs and health outcomes of the different strategies (Table 2). Strategies with longer screening intervals resulted in lower costs and less effectiveness. In comparison with no screening, the ICERs were lower than the threshold of $7485 when the screening intervals were greater than 3 years. Increasing to annual or biennial screening yielded increased QALYs and less time affected by blindness, but the marginal cost caused the ICERs to exceed the threshold.

### TABLE 2. Cost-Effectiveness of Different Diabetic Retinopathy Screening Intervals

| Strategy                  | Cost ($) | Average Time Affected by Blindness (Year) | LY     | QALY    | ICER<sup>a</sup> |
|---------------------------|----------|-------------------------------------------|--------|---------|------------------|
| No screening              | 0        | 1.304                                     | 19.158 | 11.034  | Not applicable   |
| Screening every 1 year    | 428      | 0.919                                     | 19.253 | 11.067  | 12,970           |
| Screening every 2 years   | 306      | 0.923                                     | 19.251 | 11.067  | 9273             |
| Screening every 3 years   | 260      | 0.933                                     | 19.250 | 11.067  | 7879             |
| Screening every 4 years   | 234      | 0.935                                     | 19.249 | 11.066  | 7312             |
| Screening every 5 years   | 212      | 0.946                                     | 19.248 | 11.066  | 6625             |

Note: ICER = incremental cost-effectiveness ratio, LY = life year, QALY = quality-adjusted life-years.

<sup>a</sup> Compared to no screening strategy.<sup>14</sup>

---

![FIGURE 2](image_url). Impact of the age diagnosed with type 2 diabetes on the screening frequency. The step red solid line indicates the very cost-effective screening strategy.
The 1-way sensitivity analyses revealed that some model variables had a substantial impact on the results; these variables are presented in the tornado graphs in Figure 3. The most influential variables were the age diagnosed with type 2 diabetes, followed by the probability of ME to blindness with and without photocoagulation. Other parameters, including the 3 calibrated parameters, had little to moderate effects on the model outputs.

Figure 4 shows that screening every 4 or 5 years could achieve over half the likelihood of cost-effectiveness compared to no screening at a threshold level of per capita GDP of China in 2014 ($7485).

**DISCUSSION**

To the best of our knowledge, this is the first economic evaluation of DR screening in China. Our study indicates that annual screening offers a paucity of health benefits compared to other screening intervals. According to the WHO recommendation for the cost-effectiveness threshold, >3-year screening strategies are very cost-effective for a typical newly diagnosed patient in China because the ICERs of such patients are lower than the threshold of $7485 per additional QALY gained (which represents three times the per capita GDP of China in 2014). In particular, the ICER of the 4-year screening strategy produced the greatest health outcomes relative to other screening strategies at more than 4-year screening intervals. These findings suggest that 4-year screening intervals may be a cost-effective alternative approach in the Chinese setting when costs and outcomes are considered.

The aggregated evidence from both the natural history and cost-effectiveness models favors a screening interval >1 year but ≤2 years. However, these studies were conducted in high-income areas, and it is difficult to generalize the results to low- and middle-income areas. The cost-effectiveness analysis from high-income countries revealed that annual retinal screening for all patients with T2DM without previously detected retinopathy may not be warranted on the basis of cost-effectiveness; these findings are similar to those of our research, although the economic setting differs. One economic evaluation from the Chinese Taiwan area found that annual screening for DR among Chinese patients with type 2 diabetes should be cost-effective over a 10-year time horizon because efficacy and utility decreased while cost increased with the length of the screening intervals.

The aggregated evidence from both the natural history and cost-effectiveness models favors a screening interval >1 year but ≤2 years. However, these studies were conducted in high-income areas, and it is difficult to generalize the results to low- and middle-income areas. The cost-effectiveness analysis from high-income countries revealed that annual retinal screening for all patients with T2DM without previously detected retinopathy may not be warranted on the basis of cost-effectiveness; these findings are similar to those of our research, although the economic setting differs. One economic evaluation from the Chinese Taiwan area found that annual screening for DR among Chinese patients with type 2 diabetes should be cost-effective over a 10-year time horizon because efficacy and utility decreased while cost increased with the length of the screening intervals.

The cost-effectiveness analysis from high-income countries revealed that annual retinal screening for all patients with T2DM without previously detected retinopathy may not be warranted on the basis of cost-effectiveness; these findings are similar to those of our research, although the economic setting differs. One economic evaluation from the Chinese Taiwan area found that annual screening for DR among Chinese patients with type 2 diabetes should be cost-effective over a 10-year time horizon because efficacy and utility decreased while cost increased with the length of the screening intervals.

**FIGURE 3.** Tornado diagram representing the cost per QALY gained in 1-way sensitivity analysis for screening every 4 years versus no screening. The width of the bars represents the range of the results when the variables were changed. The vertical dotted and solid line represents the base case results and threshold, respectively. DR = diabetic retinopathy; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; ME = macular edema.
However, the analysis did not note the increasing surveillance intervals once DR is detected through screening. Moreover, unlike most models, the authors did not consider mortality and the impact of DR on all-cause mortality, which may factor into the costs. Recently, 1 economic study from India reported that a 1-off DR telescreening program is cost-effective compared with no screening in the setting of rural India. The reason for the difference might be that the cost-effective threshold in India is $1320/QALY, which is nearly one-sixth the threshold in China ($7485/QALY).

We performed extensive sensitivity analyses to examine the robustness of model outcomes. The age of patients with newly diagnosed T2DM was the most influential factor for clinical and economic outcomes. When the age of newly diagnosed T2DM patients increased, the cost-effectiveness of screening every four years decreased. As shown in Figure 2, for younger patients (diagnosed at age < 40 years), screening every 3 years was cost-effective. However, for older patients, screening is only necessary every 6 (≥ 60 diagnosed age < 65 years) or >10 years (diagnosed age ≥ 65 years). These findings suggest that tailoring the screening interval according patient age could improve the cost-effectiveness of DR screening. These reports also determined that DR screening of younger patients exhibited long-term cost-effectiveness compared to no screening. On the basis of the current clinical trial and from the perspective of the Chinese healthcare system, the results of these studies are consistent with ours.

The results of this analysis must be interpreted carefully given the limitations of the data and study design. First, some of the probability estimates that were employed were obtained by the calibration method and, thus, do not avoid uncertainty although they were comparable with other published study. Sensitivity analyses demonstrate that some of these parameters exhibit a moderate impact on the cost-effectiveness of a screening strategy. Second, in the current analyses, because of the absence of relevant epidemiological studies in China, the risks of developing DR were not stratified by the risk factors, such as glycemic control, lipid levels, and blood pressure, and some of the parameter values were derived from literature that was published abroad and thus may not reflect Chinese data. Third, recent studies have revealed that vascular endothelial growth factor inhibitors can affect vision with center-involved diabetic macular edema (DME); nevertheless, we did not take this issue into account in our current model because these inhibitors are not widely prescribed in China. Fourth, we did not measure the additional benefits of an annual screening strategy, such as the early detection and intervention of glaucoma and cataracts. Finally, the results obtained from this analysis apply only to a narrow patient cohort: patients with newly diagnosed T2DM without DR. Nonetheless, because the results of this analysis reflect the clinical conditions of DR screening that are common in China, we believe that the results can serve as important reference points for Chinese decision-makers.

In conclusion, our study suggests that a 4-year screening program for DR is cost-effective compared to no screening in the Chinese setting because little benefit was achieved by 1- to 3-year screening. Varying screening frequencies might be tailored according to patient age; we believe that this focus will provide interesting insights into how to best reduce the disease burden associated with DR in China.

ACKNOWLEDGMENTS

The funding agency had no role in study design, data collection and analysis, decision to publish, or preparation of...
the manuscript. The authors would also like to thank the editor and 3 anonymous reviewers for their valuable comments and suggestions to improve the manuscript.

REFERENCES

1. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–1101.

2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–136.

3. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902–916.

4. Liu L, Wu X, Liu L, et al. Prevalence of diabetic retinopathy in Mainland China: a meta-analysis. PLoS ONE. 2012;7:e45264.

5. Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116:461–467.

6. Tung TH, Shih HC, Chen SJ, et al. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan. J Epidemiol. 2008;18:225–233.

7. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med. 2010;27:249–256.

8. Chinese Ophthalmological Society. Retinopathy Working Group: diagnosis and treatment guideline of diabetic retinopathy (2014). Chin J Ophthalmol. 2014;50:851–865.

9. Metcalf CJ, Edmunds WJ, Lessler J. Six challenges in modelling for public health policy. Epidemics. 2015;10:93–96.

10. Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making. 2012;32:701–711.

11. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–959.

12. Tu Y, Xu L, Wei WB, et al. Progression of diabetic retinopathy: the Beijing Eye Study. Chin Med J (Engl). 2011;124:3635–3640.

13. Kernick DP. Introduction to health economics for the medical practitioner. Postgrad Med J. 2003;79:147–150.

14. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62:2091–2100.

15. Task Group of the Chinese Guidelines for Pharmacoeconomic Evaluations. China Guidelines for Pharmacoeconomic Evaluations. China J Pharm Econ. 2011;3:7–48.

16. Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13:592–600.

17. Enns EA, Cipriano LE, Simons CT, et al. Identifying best-fitting inputs in health-economic model calibration: a Pareto frontier approach. Med Decis Making. 2015;35:170–182.

18. Kong CY, McMahon PM, Gazelle GS. Calibration of disease simulation model using an engineering approach. Value Health. 2009;12:521–529.

19. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124 (1 Pt 2):164–169.

20. Vijn S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889–896.

21. Kirkzilar E, Serban N, Sisson JA, et al. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology. 2013;120:2604–2610.

22. Klein R, Moss SE, Klein BE, et al. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med. 1989;149:266–272.

23. Younis N, Broadbent DM, Vora JP, et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195–200.

24. Lee VS, Kingsley RM, Lee ET, et al. The diagnosis of diabetic retinopathy. Ophthalmology versus fundus photography. Ophthalmology. 1993;100:1504–1512.

25. Shi L, Wu H, Dong J, et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol. 2015;99:823–831.

26. Fransen SR, Leonard-Martín TC, Feuer WJ, et al. Clinical evaluation of patients with diabetic retinopathy: accuracy of the laser-induced diabetic retinopathy-3DT system. Ophthalmology. 2002;109:595–601.

27. Harding SP, Broadbent DM, Neoh C, et al. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. BMJ. 1995;311:1131–1135.

28. Lin DY, Blumenkranz MS, Brothers RJ, et al. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol. 2002;134:204–213.

29. Tung TH, Chen SJ, Lee FL, et al. A community-based study for the utility values associated with diabetic retinopathy among type 2 diabetics in Kinmen, Taiwan. Diabetes Res Clin Pract. 2005;68:265–273.

30. Poku E, Brazier J, Carlton J, et al. Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review. BMC Ophthalmol. 2013;13:74.

31. Life tables for WHO Member States. http://www.who.int/gho/ countries/chn/en/. Accessed July 18, 2015.

32. National Development and Reform Commission (NDRC). http://en.ndrc.gov.cn/. Accessed July 26, 2014.

33. Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999;130:789–799.

34. List of Chinese Administrative Divisions by GDP Per Capita. http://www.stats.gov.cn/. Accessed March 28, 2015.

35. Eicher HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518–528.

36. Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235–251.

37. Echouffo-Tcheugui JB, Ali MK, Roglic G, et al. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med. 2013;30:1272–1292.

38. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12:409–418.

39. Rachapalle S, Legood R, Alavi Y, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2013;120:566–573.

40. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14:179–183.

41. Diabetic Retinopathy Clinical Research Network Wells JA, Glassman AR, et al. . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203.